Securities abbreviation: Kang Enbai Securities code: 600572 Number: Lin 2026-015
Zhejiang Conba Pharmaceutical Co., Ltd.
Announcement on the plans for some of the subsidiaries’ drugs to be selected in the continued procurement of varieties upon expiration of the national organization’s collective drug purchase agreement.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, Hangzhou Kangba Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kangba Biopharmaceutical Co., Ltd., subsidiaries of Zhejiang Kangba Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), participated in the application for the continued procurement of the 1-8 batches of nationally organized collective purchases of varieties that have expired after the agreement expires. According to the "Results of Successful Procurement of Varieties upon Expiration of the National Organized Collective Purchasing Drug Agreement" released on February 10, 2026 by the Office of Procurement of Products after the National Organization of Centralized Purchasing Drug Agreement (hereinafter referred to as the "Continuation Procurement Office"), 11 drugs including the company's tamsulosin hydrochloride sustained-release capsules, piperacillin sodium and tazobactam sodium for injection, and pantoprazole sodium enteric-coated tablets were selected for continued procurement. The relevant information is now announced as follows:
1. Basic information on the drugs to be selected
According to the rules of this continued procurement, the winning price of the drug to be selected and the quantity reported in the area to be selected are subject to the final data released by the continuing procurement office. The procurement cycle for the drugs to be selected this time is from the date of execution of the winning results to December 31, 2028.
2. The impact of this proposed election on the company
The total centralized procurement sales revenue of the above-mentioned 11 drugs to be selected in 2024 will be 385.2909 million yuan, accounting for 5.91% of the company’s operating revenue of 6.5151634 million yuan in 2024 (the data has been audited ); the total centralized purchasing sales revenue in the first three quarters of 2025 is 296.1529 million yuan, accounting for 5.95% of the company’s operating revenue of 4.9755802 million yuan in the first three quarters of 2025 (the data has not been audited).
This continuation of the procurement is the continuation of the 1-8 batches of drugs organized by the state after the agreement has expired. The winning results are expected to be implemented at the end of March 2026, that is, medical institutions in each province will begin to sign procurement contracts with manufacturers based on the winning results and purchase on a rolling basis. During this continued procurement cycle, medical institutions will give priority to using the selected drugs in this continued procurement and ensure that the agreed purchase volume is completed. The prices of the selected drugs generally remained stable or decreased. The subsequent purchase quotations of the tamsulosin hydrochloride sustained-release capsules, piperacillin-tazobactam sodium for injection, pantoprazole sodium enteric-coated tablets, finasteride tablets and other drugs to be selected by the company's subsidiaries have basically remained stable with the average sales price of the corresponding drugs in 2025.
If the proposed drug is confirmed to be selected, a purchase and sales contract is signed and implemented, it will help the company further expand the sales of related drugs, increase market share, enhance the company's brand influence, and have a positive impact on the company's future operating performance.
3. Risk warning
Subsequent matters such as the signing of the purchase contract for the above-mentioned drugs and the implementation of market sales after centralized procurement are still uncertain. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Zhejiang Conba Pharmaceutical Co., Ltd.
Board of Directors
February 13, 2026
